Evaluating Function of Parathyroid Gland Axis in Parkinson's Disease

Document Type : Original Article (s)

Authors

1 Assistant Professor, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences AND Department of Pharmacology, School of Medical Sciences, Islamic Azad University, Najafabad Branch, Isfahan, Iran

2 Associate Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, Islamic Azad University, Najafabad Branch, Isfahan, Iran

4 Student of Medicine, Young Researchers Club, Islamic Azad University, Najafabad Branch, Isfahan, Iran

Abstract

Background: Parathyroid hormone (PTH) levels can make changes in serum biomarkers and affect progression symptoms of many diseases. One of these is Parkinson's disease (PD) and according to previous studies, it seems that parathyroid gland function is effective in severity of symptoms of PD. This study aimed to explore the role of PTH in PD progression regarding the lack of researches in this field in the Middle East.Methods: This case-control study was carried out in Alzahra hospital in Isfahan, Iran. 125 patients with PD, diagnosed by experienced neurologists and 112 healthy controls matched for age and gender with patient group were asked to participate during September to November 2011. At baseline, the severity of PD was evaluated with motor part of the Unified Parkinson’s Disease Rating Scale III (UPDRS III). The level of PTH, calcium, phosphorus, and 25-hydroxy vitamin D were measured.Findings: The mean ± SD of PTH level was significantly lower in patients group (45.2 ± 18.8 IU/l) compared to controls (70.8 ± 28.5 IU/l) (P = 0.0001); there are not any significant correlation between hormone level, elements and severity of PD. We observed that men had more risk of PD than women (Odds ratio = 2.53, [CI: 1.27‑5.03], P: 0.0080).Conclusion: This study could not confirm the relationship between the level of parathyroid gland function, the level of serum PTH and severity of motor symptoms in PD. It could be explained by the lack of a sufficient number of Hypo and hypercalcemia, phosphatemia and Hypo-or hyperparathyroidism in our samples.

Keywords

References

  1. Coetzee M, Kruger MC. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment? South Med J 2004; 97(5): 506-11.
  2. Poole KE, Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 2005; 5(6): 612-7.
  3. Boron WF, Boulpaep EL. Medical physiology: a cellular and molecular approach. 1st ed. Philadelphia, PA: W.B. Saunders; 2003.
  4. Vieregge P, von MC, Friedrich HJ. Life-style and dietary factors early and late in Parkinson's disease. Can J Neurol Sci 1992; 19(2): 170-3.
  5. Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, et al. Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996; 47(3): 636-43.
  6. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5(6): 525-35.
  7. Lees AJ. Unresolved issues relating to the shaking palsy on the celebration of James Parkinson's 250th birthday. Mov Disord 2007; 22(Suppl 17): S327-S334.
  8. Simon RP, Aminoff MJ, Greenberg DA. Clinical neurology. 4th ed. Stamford, CT: Appleton & Lange; 1999.
  9. Chen JJ. Parkinson's disease and other movement disorders. Am J Geriatr Pharmacother 2010; 8(4): 293.
  10. Sato Y, Kaji M, Honda Y, Hayashida N, Iwamoto J, Kanoko T, et al. Abnormal calcium homeostasis in disabled stroke patients with low 25-hydroxyvitamin D. Bone 2004; 34(4): 710-5.
  11. Meamar R, Maracy M, Chitsaz A, Ghazvini MR, Izadi M, Tanhaei AP. Association between serum biochemical levels, related to bone metabolism and Parkinson's disease. J Res Med Sci 2013; 18(Suppl 1): S39-42.
  12. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56(1): 33-9.
  13. Lee JM, Smith JR, Philipp BL, Chen TC, Mathieu J, Holick MF. Vitamin D deficiency in a healthy group of mothers and newborn infants. Clin Pediatr (Phila) 2007; 46(1): 42-4.
  14. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 2011; 68(3): 314-9.
  15. Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78(8): 905-6.
  16. Sato Y, Kaji M, Tsuru T, Oizumi K. Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 2001; 182(2): 89-93.
  17. Wofl C, Englert S, Moghaddam AA, Zimmermann G, Schmidt-Gayk G, Honer B, et al. Time course of 25(OH)D3 vitamin D3 as well as PTH (parathyroid hormone) during fracture healing of patients with normal and low bone mineral density (BMD). BMC Musculoskelet Disord 2013; 14: 6.
  18. Himmelstein S, Clemens TL, Rubin A, Lindsay R. Vitamin D supplementation in elderly nursing home residents increases 25(OH)D but not 1,25(OH)2D. Am J Clin Nutr 1990; 52(4): 701-6.
  19. Beadle PC. Sunlight, ozone and vitamin D. Br J Dermatol 1977; 97(5): 585-91.
  20. McKenna MJ, Murray B. Vitamin D Deficiency. In: Bandeira F, Gharib H, Golbert A, Griz L, Faria M, editors. Endocrinology and Diabetes; A Problem-Oriented Approach. New York, NY: Springer; 2013. p. 293-304.
  21. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 2005; 35(5): 290-304.
  22. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 2011; 198: 221-31.
  23. Barbagallo M, Dominguez LJ, Licata G, Resnick LM. Effects of aging on serum ionized and cytosolic free calcium: relation to hypertension and diabetes. Hypertension 1999; 34(4 Pt 2): 902-6.
  24. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 2013; 698(1-3): 6-18.
  25. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients. Mov Disord 2005; 20(12): 1598-603.
  26. Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 1997; 49(5): 1273-8.
  27. Hovsepian S, Amini M, Aminorroaya A, Amini P, Iraj B. Prevalence of vitamin D deficiency among adult population of Isfahan City, Iran. J Health Popul Nutr 2011; 29(2): 149-55.
  28. Ginde AA, Liu MC, Camargo CA, Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169(6): 626-32.
  29. Sato Y, Honda Y, Hayashida N, Iwamoto J, Kanoko T, Satoh K. Vitamin K deficiency and osteopenia in elderly women with Alzheimer's disease. Arch Phys Med Rehabil 2005; 86(3): 576-81.
  30. Suzuki M, Yoshioka M, Hashimoto M, Murakami M, Noya M, Takahashi D, et al. Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr 2013; 97(5): 1004-13.
Journal of Isfahan Medical School
Volume 31, Issue 266 - Serial Number 266
November and December 2014
Pages 2122-2130

Files

History

  • Receive Date: 25 November 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics